I always wonder when reading Ray Blanco's work.... "As you know, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) recently received FDA approval for its breakthrough hepatitis C drug Incivek. Shortly after the event, I recommended taking some profits while retaining a core position. Some of our readers emailed me, reporting gains ranging from 8-51%. In the long run, Vertex isn't only about Incivek, and I think it will continue to produce new marketable therapies in hep C, cystic fibrosis as well as other indications. Since Incivek's approval came hot on the heels of the approval for Merck's Victrelis, also for hep C, my chief concern would be whether Incivek would win the majority of the market when facing off against a large competitor like Merck. I suspected, however, that Incivek's superiority would negate a lot of that advantage." But whatever the reason, I keep up with them and a variety of other 'gurus' as food for thought. My best investment was one I found myself without the help of inside knowledge. Karen